Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 3/2010

01-09-2010

Do nutraceutics play a role in the prevention and treatment of colorectal cancer?

Authors: Brian Markle, Elizabeth J. May, Adhip P. N. Majumdar

Published in: Cancer and Metastasis Reviews | Issue 3/2010

Login to get access

Abstract

Colorectal cancer is the third most common cancer worldwide with a 5-year survival of 50%. Current chemotherapeutic regimens used for advanced colorectal cancer provide an average survival of approximately 20 months. Non-toxic agents such as nutraceutics and supplements have been shown to aid in the prevention and adjuvant treatment of colorectal cancer. This article will discuss the epidemiology, progression, prevention, treatment, and recurrence of colorectal cancer and the role of nutraceutics and supplements in the treatment process.
Literature
1.
Parkin, D. M., Bray, F., Ferlay, J., et al. (2005). Global cancer statistics, 2002. CA: A Cancer Journal for Clinicians, 55, 74–108.CrossRef
2.
Jemal, A., Siegel, R., Ward, E., et al. (2009). Cancer statistics, 2009. CA: A Cancer Journal for Clinicians, 59, 225–249.CrossRef
3.
Rex, D. K., Johnson, D. A., Anderson, J. C., et al. (2009). American college of gastroenterology guidelines for colorectal cancer screening 2008. The American Journal of Gastroenterology, 104, 739–750.CrossRefPubMed
4.
Winawer, S., Fletcher, R., Rex, D., et al. (2003). Colorectal cancer screening and surveillance: clinical guidelines and rationale—Update based on new evidence. Gastroenterology, 124, 544–560.CrossRefPubMed
5.
Patel, B. B., Yu, Y., Du, J., et al. (2009). Age-related increase in colorectal cancer stem cells in macroscopically normal mucosa of patients with adenomas: a risk factor for colon cancer. Biochemical and Biophysical Research Communications, 378, 344–347.CrossRefPubMed
6.
Davila, R. E., Rajan, E., Baron, T. H., et al. (2006). ASGE guideline: colorectal cancer screening and surveillance. Gastrointestinal Endoscopy, 63, 546–557.CrossRefPubMed
7.
Robbins, D. H., & Itzkowitz, S. H. (2002). The molecular and genetic basis of colon cancer. The Medical Clinics of North America, 86, 1467–1495.CrossRefPubMed
8.
Kanwar, S. S., Nautiyal, J., & Majumdar, A. P. (2010). EGFR(s) inhibitors in the treatment of gastro-intestinal cancers: what’s new? Current Drug Targets, 11, 682–698.CrossRefPubMed
9.
Pino, M. S., & Chung, D. C. (2010). The chromosomal instability pathway in colon cancer. Gastroenterology, 138, 2059–2072.CrossRefPubMed
10.
Salama, P., & Platell, C. (2009). Colorectal cancer stem cells. ANZ Journal of Surgery, 79, 697–702.CrossRefPubMed
11.
Friedlich, M. S. S. (2002). Prevention of colorectal cancer. Canadian Journal of CME, 14, 112–119.
12.
Chan, A. T., & Giovannucci, E. L. (2010). Primary prevention of colorectal cancer. Gastroenterology, 138, 2029–2043.CrossRefPubMed
13.
Nautiyal, J., Kanwar, S. S., & Majumdar, A. P. (2010). EGFR(s) in saging and carcinogenesis of the gastrointestinal tract. Current Protein & Peptide Science, 11, 436–450.CrossRef
14.
Winawer, S. J. (2007). Colorectal cancer screening. Best Practice & Research. Clinical Gastroenterology, 21, 1031–1048.CrossRef
15.
Sleisenger, M. H. (2006). Sleisenger & Fordtran’s gastrointestinal and liver disease Pathophysiology, diagnosis, management. St. Louis, Mo: W.B. Saunders.
16.
Yu, Y., Kanwar, S. S., Patel, B. B., et al. (2009). Elimination of colon cancer stem-like cells by the combination of curcumin and FOLFOX. Transl Oncol, 2, 321–328.PubMed
17.
Kalra, E. (2003). Nutraceutical-definition and introduction. The AAPS Journal, 5, 27–28.
18.
Majumdar, A. P., Kodali, U., & Jaszewski, R. (2004). Chemopreventive role of folic acid in colorectal cancer. Frontiers in Bioscience, 9, 2725–2732.CrossRefPubMed
19.
Laanpere, M., Altmae, S., Stavreus-Evers, A., et al. (2010). Folate-mediated one-carbon metabolism and its effect on female fertility and pregnancy viability. Nutrition Reviews, 68, 99–113.CrossRefPubMed
20.
Vecchia, C. L., Negri, E., Pelucchi, C., et al. (2002). Dietary folate and colorectal cancer. International Journal of Cancer, 102, 545–547.CrossRef
21.
Lashner, B. A., Heidenreich, P. A., Su, G. L., Kane, S. V., & Hanauer, S. B. (1989). Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis: A case-control study (97th ed.). New York: Elsevier. ETATS-UNIS.
22.
Kim, Y. I. (2003). Role of folate in colon cancer development and progression. Journal of Nutrition, 133(11 Suppl 1), 3731S–3739S.PubMed
23.
Sanjoaquin, M. A., Allen, N., Couto, E., et al. (2005). Folate intake and colorectal cancer risk: a meta-analytical approach. International Journal of Cancer, 113, 825–828.CrossRef
24.
Jaszewski, R., Misra, S., Tobi, M., et al. (2008). Folic acid supplementation inhibits recurrence of colorectal adenomas: a randomized chemoprevention trial. World Journal of Gastroenterology, 14, 4492–4498.CrossRefPubMed
25.
Jaszewski, R., Khan, A., Sarkar, F. H., et al. (1999). Folic acid inhibition of EGFR-mediated proliferation in human colon cancer cell lines. The American Journal of Physiology, 277, C1142–C1148.PubMed
26.
Kim, Y. I. (2007). Folate and colorectal cancer: an evidence-based critical review. Molecular Nutrition & Food Research, 51, 267–292.CrossRef
27.
Van der Meer, R., & De Vries, H. T. (1985). Differential binding of glycine- and taurine-conjugated bile acids to insoluble calcium phosphate. The Biochemical Journal, 229, 265–268.PubMed
28.
Pence, B. C., & Buddingh, F. (1988). Inhibition of dietary fat-promoted colon carcinogenesis in rats by supplemental calcium or vitamin D3. Carcinogenesis, 9, 187–190.CrossRefPubMed
29.
Baron, J. A., Beach, M., Mandel, J. S., et al. (1999). Calcium supplements for the prevention of colorectal adenomas. Calcium polyp prevention study group. The New England Journal of Medicine, 340, 101–107.CrossRefPubMed
30.
Newmark, H. L., Wargovich, M. J., & Bruce, W. R. (1984). Colon cancer and dietary fat, phosphate, and calcium: a hypothesis. Journal of the National Cancer Institute, 72, 1323–1325.PubMed
31.
Lipkin, M., & Newmark, H. (1985). Effect of added dietary calcium on colonic epithelial-cell proliferation in subjects at high risk for familial colonic cancer. The New England Journal of Medicine, 313, 1381–1384.CrossRefPubMed
32.
Garland, C. F., & Garland, F. C. (2006). Do sunlight and vitamin D reduce the likelihood of colon cancer? International Journal of Epidemiology, 35, 217–220.CrossRefPubMed
33.
Ng, K., Meyerhardt, J. A., Wu, K., et al. (2008). Circulating 25-hydroxyvitamin d levels and survival in patients with colorectal cancer. Journal of Clinical Oncology, 26, 2984–2991.CrossRefPubMed
34.
Chakrabarty, S., Wang, H., Canaff, L., et al. (2005). Calcium sensing receptor in human colon carcinoma: interaction with Ca(2+) and 1, 25-dihydroxyvitamin D(3). Cancer Research, 65, 493–498.PubMed
35.
Wang, X. T., Nagaba, Y., Cross, H. S., et al. (2000). The mRNA of L-type calcium channel elevated in colon cancer: protein distribution in normal and cancerous colon. The American Journal of Pathology, 157, 1549–1562.PubMed
36.
Peterlik, M., Grant, W. B., & Cross, H. S. (2009). Calcium, vitamin D and cancer. Anticancer Research, 29, 3687–3698.PubMed
37.
Lieberman, D. A., Prindiville, S., Weiss, D. G., et al. (2003). Risk factors for advanced colonic neoplasia and hyperplastic polyps in asymptomatic individuals. JAMA, 290, 2959–2967.CrossRefPubMed
38.
Diaz, G. D., Paraskeva, C., Thomas, M. G., et al. (2000). Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy. Cancer Research, 60, 2304–2312.PubMed
39.
Taghizadeh, F., Tang, M. J., & Tai, I. T. (2007). Synergism between vitamin D and secreted protein acidic and rich in cysteine-induced apoptosis and growth inhibition results in increased susceptibility of therapy-resistant colorectal cancer cells to chemotherapy. Molecular Cancer Therapeutics, 6, 309–317.CrossRefPubMed
40.
Martinez, M. E., & Willett, W. C. (1998). Calcium, vitamin D, and colorectal cancer: a review of the epidemiologic evidence. Cancer Epidemiology, Biomarkers & Prevention, 7, 163–168.
41.
Shaukat, A., Scouras, N., & Schunemann, H. J. (2005). Role of supplemental calcium in the recurrence of colorectal adenomas: a metaanalysis of randomized controlled trials. The American Journal of Gastroenterology, 100, 390–394.CrossRefPubMed
42.
Hanif, R., Qiao, L., Shiff, S. J., et al. (1997). Curcumin, a natural plant phenolic food additive, inhibits cell proliferation and induces cell cycle changes in colon adenocarcinoma cell lines by a prostaglandin-independent pathway. The Journal of Laboratory and Clinical Medicine, 130, 576–584.CrossRefPubMed
43.
Gamelin, L., Boisdron-Celle, M., Delva, R., et al. (2004). Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clinical Cancer Research, 10, 4055–4061.CrossRefPubMed
44.
Kurniali, P. C., Luo, L. G., & Weitberg, A. B. (2010). Role of calcium/magnesium infusion in oxaliplatin-based chemotherapy for colorectal cancer patients. Oncology (Williston Park), 24, 289–292.
45.
Perkins, S., Verschoyle, R. D., Hill, K., et al. (2002). Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis. Cancer Epidemiology, Biomarkers & Prevention, 11, 535–540.
46.
Barnes, C. J., & Lee, M. (1998). Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin. Gastroenterology, 114, 873–877.CrossRefPubMed
47.
Aggarwal, B. B., Ichikawa, H., Garodia, P., et al. (2006). From traditional Ayurvedic medicine to modern medicine: identification of therapeutic targets for suppression of inflammation and cancer. Expert Opinion on Therapeutic Targets, 10, 87–118.CrossRefPubMed
48.
Cantorna, M. T., Munsick, C., Bemiss, C., et al. (2000). 1, 25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. The Journal of Nutrition, 130, 2648–2652.PubMed
49.
Fedirko, V., Bostick, R. M., Flanders, W. D., et al. (2009). Effects of vitamin d and calcium on proliferation and differentiation in normal colon mucosa: a randomized clinical trial. Cancer Epidemiology, Biomarkers & Prevention, 18, 2933–2941.CrossRef
50.
Newmark, H. L., Yang, K., Kurihara, N., et al. (2009). Western-style diet-induced colonic tumors and their modulation by calcium and vitamin D in C57Bl/6 mice: a preclinical model for human sporadic colon cancer. Carcinogenesis, 30, 88–92.CrossRefPubMed
51.
Hartman, T. J., Albert, P. S., Snyder, K., et al. (2005). The association of calcium and vitamin D with risk of colorectal adenomas. The Journal of Nutrition, 135, 252–259.PubMed
52.
Villegas, I., Sanchez-Fidalgo, S., & Arcon de la Lastra, C. (2008). New mechanisms and therapeutic potential of curcumin for colorectal cancer. Molecular Nutrition & Food Research, 52, 1040–1061.CrossRef
53.
Grant, K. L. P., & Schneider, C. D. M. D. (2000). Turmeric. [Miscellaneous Article]. American Journal of Health-System Pharmacy, 57, 1121–1122.PubMed
54.
Patel, B. B., & Majumdar, A. P. N. (2009). Synergistic role of curcumin with current therapeutics in colorectal cancer: minireview. Nutrition and Cancer, 61, 842–846.CrossRefPubMed
55.
Kawamori, T., Lubet, R., Steele, V. E., et al. (1999). Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. Cancer Research, 59, 597–601.PubMed
56.
Sharma, R. A., Euden, S. A., Platton, S. L., et al. (2004). Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clinical Cancer Research, 10, 6847–6854.CrossRefPubMed
57.
Patel, B. B., Sengupta, R., Qazi, S., et al. (2008). Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R. International Journal of Cancer, 122, 267–273.CrossRef
58.
Kunnumakkara, A. B., Diagaradjane, P., Anand, P., et al. (2009). Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model. International Journal of Cancer, 125, 2187–2197.CrossRef
59.
Adachi, Y., Lee, C. T., Coffee, K., et al. (2002). Effects of genetic blockade of the insulin-like growth factor receptor in human colon cancer cell lines. Gastroenterology, 123, 1191–1204.CrossRefPubMed
60.
Hakam, A., Yeatman, T. J., Lu, L., et al. (1999). Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Human Pathology, 30, 1128–1133.CrossRefPubMed
61.
Wang, J. C., & Dick, J. E. (2005). Cancer stem cells: lessons from leukemia. Trends in Cell Biology, 15, 494–501.CrossRefPubMed
62.
63.
Patel, B. B., Gupta, D., Elliott, A. A., et al. (2010). Curcumin targets FOLFOX-surviving colon cancer cells via inhibition of EGFRs and IGF-1R. Anticancer Research, 30, 319–325.PubMed
Metadata
Title
Do nutraceutics play a role in the prevention and treatment of colorectal cancer?
Authors
Brian Markle
Elizabeth J. May
Adhip P. N. Majumdar
Publication date
01-09-2010
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 3/2010
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-010-9234-3

Other articles of this Issue 3/2010

Cancer and Metastasis Reviews 3/2010 Go to the issue

ReviewPaper

Cancer and metastasis: prevention and treatment by green tea

Acknowledgments

Biography—Fazlul H. Sarkar, Ph.D.

OriginalPaper

Tomato-based food products for prostate cancer prevention: what have we learned?

OriginalPaper

Inhibition of cancer cell invasion and metastasis by genistein

OriginalPaper

Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer

EditorialNotes

Preface
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits